AIMS: To develop a population pharmacokinetic model for stavudine in children and to investigate the consistency of the currently recommended dose based on adult target concentrations. METHODS: The pharmacokinetics of stavudine were investigated using a population approach. Individual estimates of CL/F were used to calculate the stavudine dose required to achieve the area under the concentration-time curve reported in adults given recommended doses. RESULTS: Stavudine pharmacokinetics were well described by a one-compartment model with zero-order absorption. Typical population estimates (% interindividual variability) of the apparent distribution volume (V/F) and plasma clearance (CL/F) were 40.9 l (32%) and 16.5 l h(-1) (38%), respectively. Stavudine V/F and CL/F were similarly related to age. Mean calculated doses (0.61 mg kg(-1) for children less than 2 weeks, 1.23 mg kg(-1) for children more than 2 weeks with bodyweight less than 30 kg, and 31.5 mg for children with a bodyweight between 30 and 60 kg) were in agreement with the current paediatric doses (0.5 mg kg(-1), 1 mg kg(-1), and 30 mg, respectively). CONCLUSIONS: Our findings support the current recommended paediatric dosage regimens for stavudine, as they result in the same exposure to the drug as in adults.
AIMS: To develop a population pharmacokinetic model for stavudine in children and to investigate the consistency of the currently recommended dose based on adult target concentrations. METHODS: The pharmacokinetics of stavudine were investigated using a population approach. Individual estimates of CL/F were used to calculate the stavudine dose required to achieve the area under the concentration-time curve reported in adults given recommended doses. RESULTS:Stavudine pharmacokinetics were well described by a one-compartment model with zero-order absorption. Typical population estimates (% interindividual variability) of the apparent distribution volume (V/F) and plasma clearance (CL/F) were 40.9 l (32%) and 16.5 l h(-1) (38%), respectively. Stavudine V/F and CL/F were similarly related to age. Mean calculated doses (0.61 mg kg(-1) for children less than 2 weeks, 1.23 mg kg(-1) for children more than 2 weeks with bodyweight less than 30 kg, and 31.5 mg for children with a bodyweight between 30 and 60 kg) were in agreement with the current paediatric doses (0.5 mg kg(-1), 1 mg kg(-1), and 30 mg, respectively). CONCLUSIONS: Our findings support the current recommended paediatric dosage regimens for stavudine, as they result in the same exposure to the drug as in adults.
Authors: C V Fletcher; R C Brundage; R P Remmel; L M Page; D Weller; N R Calles; C Simon; M W Kline Journal: Antimicrob Agents Chemother Date: 2000-04 Impact factor: 5.191
Authors: Nancy A Wade; Jashvant D Unadkat; Sharon Huang; David E Shapiro; Anita Mathias; Salih Yasin; Gregory Ciupak; D Heather Watts; Isaac Delke; Mobeen Rathore; Jane Hitti; Lisa Frenkel; Renee Samelson; Mary Elizabeth Smith; Lynne Mofenson; Sandra K Burchett Journal: J Infect Dis Date: 2004-11-10 Impact factor: 5.226
Authors: C Rongkavilit; P Thaithumyanon; T Chuenyam; B D Damle; S Limpongsanurak; C Boonrod; A Srigritsanapol; E A Hassink; R M Hoetelmans; D A Cooper; J M Lange; K Ruxrungtham; P Phanuphak Journal: Antimicrob Agents Chemother Date: 2001-12 Impact factor: 5.191
Authors: François Becher; Roland Landman; S Mboup; C Ndeye Toure Kane; Ana Canestri; Florent Liegeois; Murielle Vray; Marie-Helene Prevot; Ghislaine Leleu; Henri Benech Journal: AIDS Date: 2004-01-23 Impact factor: 4.177
Authors: Gregory L Kearns; Susan M Abdel-Rahman; Sarah W Alander; Douglas L Blowey; J Steven Leeder; Ralph E Kauffman Journal: N Engl J Med Date: 2003-09-18 Impact factor: 91.245
Authors: M W Kline; L M Dunkle; J A Church; J C Goldsmith; A T Harris; M E Federici; M E Schultze; L Woods; D F Loewen; S Kaul Journal: Pediatrics Date: 1995-08 Impact factor: 7.124
Authors: C M Horton; M N Dudley; S Kaul; K H Mayer; K Squires; L Dunkle; R Anderson Journal: Antimicrob Agents Chemother Date: 1995-10 Impact factor: 5.191
Authors: Sherwin K B Sy; Ruben Malmberg; Aoi Matsushima; Eduardo Asin-Prieto; Bernd Rosenkranz; Mark F Cotton; Hartmut Derendorf; Steve Innes Journal: Int J Antimicrob Agents Date: 2015-01-19 Impact factor: 5.283
Authors: Sherwin K B Sy; Steve Innes; Hartmut Derendorf; Mark F Cotton; Bernd Rosenkranz Journal: Antimicrob Agents Chemother Date: 2013-12-02 Impact factor: 5.191